TSTickerStarGet alerts

MDCX Call: 30%+ ORR Target for Pfizer-Partnered ADC; SkinJect SPAC Details and OpEx Reduction

Medicus Pharma (MDCX) management used its Q3 2026 call to provide critical clinical benchmarks for its lead ADC asset and clarify the mechanics of the proposed SkinJect spin-off. The most significant incremental detail was the establishment of a 30% objective response rate (ORR) target for CD228V in immunotherapy-resistant melanoma, a benchmark management believes could support a monotherapy registration strategy. Furthermore, the company signaled a pivot toward extreme capital efficiency, with the CFO forecasti...

Share this story

What changed on the call

Incremental information and investor implications beyond the release.

  • CD228V Clinical Benchmark

    Management is targeting an ORR exceeding 30% in melanoma patients who have failed immunotherapy. This target is informed by Seagen's original 88-patient study and Pfizer's subsequent 11-patient study of the refined molecule.

    Establishing a clear efficacy hurdle allows investors to model the probability of a monotherapy registration path versus more complex combination trials.
  • SkinJect SPAC Strategy

    The proposed business combination with an undisclosed SPAC values SkinJect at $135M pre-money. Medicus intends to retain majority economic and voting ownership while shifting the ~$3M two-year development budget to the new entity.

    This 'unlocks' value for MDCX shareholders while removing the cash burn associated with SkinJect from the MDCX balance sheet.
  • Operating Expense Pivot

    Following a Q3 where OpEx reached $14.5M (including a $10M non-cash charge for the Pfizer deal), management expects a significant downward trend in spending.

    With $13.1M in total cash, the company must reduce burn to reach the H1 2027 SPAC closing and clinical milestones without immediate dilutive financing.

Guidance and model clarifications

Operating Expenses
CFO Carolyn Bonner explicitly stated the company anticipates a 'substantial reduction' in operating expenses in the coming quarters.New versus the release
SkinJect Development Budget
Management quantified the SkinJect 005 study and NDA preparation budget at approximately $3M spread over the next two years.New versus the release
SPAC Closing Timeline
The company currently anticipates completing the SkinJect business combination during the first half of 2027.New versus the release

Analyst Q&A

Clinical Timelines for CD228V

Kumar Raja (Brookline Capital)

CMO Faisal Mehmud noted they are 60 days into the Pfizer deal and are currently constructing an 'efficient development plan' leveraging existing Seagen/Pfizer data to reach a decision point quickly.

Investor read-through: The company is avoiding a 'start from scratch' approach, which should shorten the time to the next major clinical data catalyst.

SkinJect SPAC Execution

Kumar Raja (Brookline Capital)

CEO Bokhari clarified that clinical progress on SkinJect 005 will continue in parallel with the SPAC transaction and will not wait for the deal to close.

Investor read-through: The transaction is a financial engineering move, not a reason to pause clinical development.

Efficacy Benchmarks

Chad Yen (Maxim Group)

Management reiterated the 30% ORR target and noted that the study design already includes expansion cohorts for squamous lung, esophageal, and head and neck cancers.

Investor read-through: Melanoma is the 'beachhead' for registration, but the platform has broader solid tumor optionality already baked into the trial design.

Risks and watch items

  • SPAC Transaction Uncertainty

    The LOI for the SkinJect deal is non-binding; there is no guarantee a definitive agreement will be signed or that financing will be secured.

  • Taveralix CMC Snags

    Management admitted to 'snags' in the manufacturing (CMC) of Taveralix that were out of their control, though they expect the product to be ready by Q1 2027.

  • FDA Feedback

    The optimized prostate cancer protocol for Taveralix is currently awaiting FDA feedback (approaching a 45-day mark).

Management tone

  • Pfizer Collaboration

    CEO Raza Bokhari emphasized that the Vedotin linker-payload refinements were specifically designed to improve the balance between drug exposure and anti-tumor activity.

    Highly confident in the 'second-generation' refinements made to the ADC molecule.
  • Asset Prioritization

    Management repeatedly used the term 'partner-ready' for Taveralix, signaling they will not spend MDCX capital to advance it further without a collaborator.

    Pragmatic and disciplined regarding non-core assets.

Reinforced on the call

  • Pfizer Option

    Pfizer retains the right (but not the obligation) to fund all or part of the development beginning with the first pivotal trial.

  • Cash Position

    The company held $13.1M in combined cash as of Sept 30, 2026, necessitating the mentioned OpEx reductions.

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open Earnings call webcast

Follow MDCX in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert